Wells Fargo
STRO icon

Wells Fargo’s Sutro Biopharma STRO Stock Holding History

Wells Fargo’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$1.16K – 7443
2025
Q4 		$1.16K Buy
+100
New +$949 ﹤0.01% 6273
2025
Q3 		– Sell
-69
Closed -$495 – 7376
2025
Q2 		$495 Sell
69
-4,844
-99% -$39.6K ﹤0.01% 6374
2025
Q1 		$32K Sell
4,913
-361
-7% -$5.68K ﹤0.01% 5543
2024
Q4 		$97K Buy
5,274
+1,047
+25% +$32K ﹤0.01% 5217
2024
Q3 		$146K Buy
4,227
+41
+1% +$1.61K ﹤0.01% 4782
2024
Q2 		$123K Buy
4,186
+1,449
+53% +$57.3K ﹤0.01% 4811
2024
Q1 		$155K Buy
2,737
+420
+18% +$18.6K ﹤0.01% 4628
2023
Q4 		$99.4K Buy
2,317
+365
+19% +$11.6K ﹤0.01% 4901
2023
Q3 		$67.7K Sell
1,952
-806
-29% -$35.1K ﹤0.01% 5011
2023
Q2 		$128K Sell
2,758
-2,258
-45% -$112K ﹤0.01% 4877
2023
Q1 		$232K Buy
5,016
+4,447
+782% +$282K ﹤0.01% 4335
2022
Q4 		$46K Buy
569
+437
+331% +$30.4K ﹤0.01% 4902
2022
Q3 		$8K Sell
132
-143
-52% -$8.46K ﹤0.01% 5781
2022
Q2 		$14K Sell
275
-3,536
-93% -$198K ﹤0.01% 5618
2022
Q1 		$313K Sell
3,811
-1,411
-27% -$134K ﹤0.01% 4719
2021
Q4 		$777K Sell
5,222
-6,060
-54% -$1.09M ﹤0.01% 4316
2021
Q3 		$2.13M Sell
11,282
-2,735
-20% -$520K ﹤0.01% 3619
2021
Q2 		$2.61M Sell
14,017
-357
-2% -$69.9K ﹤0.01% 3449
2021
Q1 		$3.27M Buy
14,374
+8,099
+129% +$1.92M ﹤0.01% 3262
2020
Q4 		$1.36M Buy
6,275
+1,706
+37% +$282K ﹤0.01% 3790
2020
Q3 		$459K Buy
4,569
+1,501
+49% +$142K ﹤0.01% 4411
2020
Q2 		$238K Buy
3,068
+922
+43% +$88.5K ﹤0.01% 4808
2020
Q1 		$218K Buy
2,146
+204
+11% +$21.4K ﹤0.01% 4627
2019
Q4 		$213K Buy
1,942
+548
+39% +$56.5K ﹤0.01% 4916
2019
Q3 		$127K Buy
1,394
+246
+21% +$24.8K ﹤0.01% 5209
2019
Q2 		$130K Buy
1,148
+811
+241% +$89.4K ﹤0.01% 5191
2019
Q1 		$38K Buy
337
+7
+2% +$728 ﹤0.01% 5388
2018
Q4 		$30K Buy
+330
New +$39.8K ﹤0.01% 5680

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wells Fargo's STRO Position: Q1 2026 in Review

Wells Fargo sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 100 shares — an estimated $1.16K sold.

Wells Fargo first reported a position in STRO in Q4 2018 and held it in 28 quarters. The position peaked at $3.27M in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Wells Fargo reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 100 Sutro Biopharma shares in Q1 2026, an estimated $1.16K.
  • Wells Fargo first reported a position in Sutro Biopharma in Q4 2018 and held it in 28 quarters.
  • Wells Fargo's Sutro Biopharma position peaked at $3.27M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.